David Kabakoff

A chemist by training, the companies that David has led as President, CEO, or Chairman have produced billions of dollars in returns for investors and employees. He currently serves on the Boards of HealthQuest portfolio companies Lineagen, Castle Biosciences (CSTL), and Biotheranostics (in addition to RareCyte). As an operator, David’s successes include leading the development of some of the diagnostic industry’s most iconic products like the first yes/no color changing pregnancy test, the PSA test for prostate cancer, and the rapid strep throat test, plus numerous cancer diagnostics. He served in senior executive positions at Hybritech, was EVP of Dura Pharmaceuticals, CEO of Spiros Development Corp., Corvas International, and co-founder/CEO of Salmedix. Each of the products he developed succeeded because it made a large impact on the medical management of patients. He has served as Chairman of Trius Therapeutics (acquired by Cubist), Chairman of Cebix Inc., Chairman of Amplimmune, Inc. (acquired by AstraZeneca), and as a Director of InterMune, Inc. (acquired by Roche), and Allylix, Inc. (acquired by Evolva). David earned his BA in chemistry from Case Western Reserve University and then his Ph.D. from Yale University. He lives with his wife and enjoys fine wine, travel, and skiing.